The invention relates to NEP inhibitors for treating cardiovascular disorders.
Preferred NEP inhibitors are compounds of formula (I) wherein R1 is
C1-C6alkyl, C1-C6alkoxyC1-C3alkyl
or C1-C6alkoxyC1-C6alkoxyC1-C3alkyl;
R2 is hydrogen or C1-C6alkyl; L is a three atom
linkage selected from —CH2—X—CH2—
and —CH2—CH2—X— where the right hand
side of the linkage is attached to R3 and where X is oxygen, sulfur
or methylene; R3 is phenyl or aromatic heterocyclyl, either of which
may be independently substituted by one or more groups selected from: C1-C6alkyl,
halo, haloC1-C6alkyl, C1-C6alkoxy,
haloC1-C6alkoxy, C1-C6alkylthio, haloC1-C6alkylthio
and nitrile; and R4 and R5 are either both hydrogen, or one
of R4 and R5 is hydrogen and the other is a biolabile ester-forming
group that in the body of a patient is replaced by hydrogen.
##STR1##
